Cerebral venous thrombosis is a rare but potentially life-threatening condition that is particularly prevalent in young women (ie, mean age 44 years) and accounts for 0·5–3% of all strokes. The ...

Endovascular Engineering (E2) announced today that it raised $42 million in an oversubscribed Series B financing round.

Sweden: A recent study published in the Journal of Internal Medicine has highlighted an elevated risk of bleeding in patients ...

Purpose. The use of anticoagulant therapy for the prevention and treatment of venous thromboembolism (VTE) and acute coronary syndrome (ACS) among hospital inpatients was evaluated. Methods.

Ongoing trials in other indications, including treatment of VTE and stroke prevention in patients with atrial fibrillation, is where these new agents will probably demonstrate their greatest ...

Endovascular Engineering, Inc. (E2) announced it has secured $42 million in oversubscribed Series B financing to advance its n ...

Data sources: Published, randomized controlled trials (RCTs) of OAC treatment of VTE. Study selection: RCTs of varying durations of OAC treatment of VTE that include VTE recurrence (or extension ...

Considering taking supplements to treat venous thromboembolism vte? Below is a list of common natural remedies used to treat or reduce the symptoms of venous thromboembolism vte. Follow the links ...

Endovascular Engineering (E2) has secured an oversubscribed $42m in a Series B funding round to further its clot removal ...